News
KIST-Kwangdong Pharmaceutical Hold Technology Transfer Signing Ceremony and Linking Lab Signboard Ceremony (February 7, 2022)
- Date : 2022-03-15
- Views : 350
-
Writer
International Cooperation Team
-
Att.
KIST-Kwangdong Pharmaceutical Hold Technology Transfer Signing Ceremony and Linking Lab Signboard Ceremony
On February 7, the Korea Institute of Science and Technology (KIST; President: Dr. Seok-Jin Yoon) held a signboard hanging ceremony to commemorate the opening of Linking Lab for collaborative R&D efforts, as well as a technology transfer signing ceremony between the KIST Gangneung Institute of Natural Products and Kwangdong Pharmaceutical (CEO: Sung Won Choi) for the identification and industrial production of integrated food-drug natural product candidate substances using in-vivo and in-vitro efficacy verification methods, and a signboard hanging ceremony to commemorate the opening of Linking Lab, which was established to facilitate joint R&D efforts.
Dr. Sang Hoon Jung’s team at KIST's Natural Products
Research Center utilized in-vitro efficacy verification to evaluate the functionality
of more than 100 natural product extracts in terms of gum health, joint health,
immune function health, and other aspects, and identify potential integrated
food-drug natural product candidates. In order to commercialize the related
technologies, Dr. Jung’s team transferred them to Kwangdong Pharmaceutical and
established Linking Lab, which will also function as a joint laboratory.
Linking Lab is a project launched in 2021 to actively
support the commercialization process for cutting-edge technologies by
companies which have signed technology transfer contracts. By providing a space
where technology producers and developers can jointly conduct research together
in the same laboratory, the producers are able to actively support technology
development, and the developers can strengthen their research capabilities, thereby
increasing the possibility of commercialization.
KIST plans to conduct a cooperative study on candidate
materials for gum health, joint health, and immune functional health through
the Linking Lab project with Kwangdong Pharmaceutical, and hopefully identify additional
functionalities in these materials. The joint research team will conduct in-vivo
efficacy verifications and complete pre-testing for human trials in 2022. In
addition, KIST and Kwangdong Pharmaceutical have also decided to continue cooperating
on pre-clinical research for the drug development of various natural products
even after this R&D process has concluded.
Dr. Yoon, President of KIST, stated, "The main
obstacle to the industrialization of basic research has been the gap between
companies and research institutes regarding what technologies are in demand in
the markets and communication problems. KIST will spare no effort to minimize
the gap between research and industrialization and maximize the possibility of successful
commercialization through company-oriented joint research."
An official from Kwangdong Pharmaceutical commented,
"Based on our management ideology of ‘creating new value and contributing
to the healthy life of our customers,’ we will make constant efforts to cooperate
with KIST to discover, foster, and industrialize integrated food-drug natural
products."
KIST's research team has succeeded in testing
individually recognized health functional foods several times through long-term
research on natural food and drug development, and has also acquired excellent
technological capabilities in related fields, ranging from basic source technologies
to industrialization research such as the clinical recognition of naturally
produced medicines.
Kwangdong Pharmaceutical was founded under the ideology of the scientific development of Eastern medicine, and since its establishment in 1963, is recognized for producing papers proving proving the efficacy of many natural remedies, including Woohwang-cheongsimwon, and modernizing the prescription of Gyeongokgo, a traditional herbal medicine. Using this knowledge and its GMP facilities, the company intends to contribute to the discovery and commercialization of new materials together with KIST.